INNBC DApp, a decentralized application to permanently store biomedical data on a modern, proof-of-stake (POS), blockchain such as BNB Smart Chain.

BACKGROUND: A blockchain can be described as a distributed ledger database where, under a consensus mechanism, data are permanently stored in records, called blocks, linked together with cryptography. Each block contains a cryptographic hash function of the previous block, a timestamp, and transaction data, which are permanently stored in thousands of nodes and never altered. This provides a potential real-world application for generating a permanent, decentralized record of scientific data, taking advantage of blockchain features such as timestamping and immutability. IMPLEMENTATION: Here, we propose INNBC DApp, a Web3 decentralized application providing a simple front-end user interface connected with a smart contract for recording scientific data on a modern, proof-of-stake (POS) blockchain such as BNB Smart Chain. Unlike previously proposed blockchain tools that only store a hash of the data on-chain, here the data are stored fully on-chain within the transaction itself as "transaction input data", with a true decentralized storage solution. In addition to plain text, the DApp can record various types of files, such as documents, images, audio, and video, by using Base64 encoding. In this study, we describe how to use the DApp and perform real-world transactions storing different kinds of data from previously published research articles, describing the advantages and limitations of using such a technology, analyzing the cost in terms of transaction fees, and discussing possible use cases. RESULTS: We have been able to store several different types of data on the BNB Smart Chain: raw text, documents, images, audio, and video. Notably, we stored several complete research articles at a reasonable cost. We found a limit of 95KB for each single file upload. Considering that Base64 encoding increases file size by approximately 33%, this provides us with a theoretical limit of 126KB. We successfully overcome this limitation by splitting larger files into smaller chunks and uploading them as multi-volume archives. Additionally, we propose AES encryption to protect sensitive data. Accordingly, we show that it is possible to include enough data to be useful for storing and sharing scientific documents and images on the blockchain at a reasonable cost for the users. CONCLUSION: INNBC DApp represents a real use case for blockchain technology in decentralizing biomedical data storage and sharing, providing us with features such as immutability, timestamp, and identity that can be used to ensure permanent availability of the data and to provide proof-of-existence as well as to protect authorship, a freely available decentralized science (DeSci) tool aiming to help bring mass adoption of blockchain technology among the scientific community.

SupT1 Cell Infusion as a Possible Cell-Based Therapy for HIV: Results from a Pilot Study in Hu-PBMC BRGS Mice.

In a previous in vitro study, the SupT1 cell line was explored as a decoy target for HIV-1, proposing SupT1 cell infusion as a possible cell-based therapy for HIV. In the present work, the previous in vitro model was translated into an in vivo setting. Specifically, Hu-PBMC BRGS mice were infected with a high input of HIV-1 LAI (100,000 TCID50), and 40 million 30 Gy-irradiated SupT1 cells were infused weekly for 4 weeks as a therapy. Blood samples were taken to monitor CD4+ T cell count and viral load, and mice were monitored daily for signs of illness. At the earliest time point analyzed (Week 1), there was a significantly lower plasma viral load (~10-fold) in all animals treated with SupT1 cell infusion, associated with a higher CD4+ T cell count. At later time points, infection proceeded with robust viral replication and evident CD4+ T cell depletion, except in one mouse that showed complete suppression of viral replication and preservation of CD4+ T cell count. No morbidity or mortality was associated with SupT1 cell infusion. The interesting tendencies observed in the generated data suggest that this approach should be further investigated as a possible cell-based HIV therapy.

Salamander regeneration as a model for developing novel regenerative and anticancer therapies.

Among vertebrates, urodele amphibians are the only tetrapods with the ability to regenerate complex structures such as limbs, tail, and spinal cord throughout their lives. Furthermore, the salamander regeneration process has been shown to reverse tumorigenicity. Fibroblasts are essential for salamander regeneration, but the mechanisms underlying their role in the formation of a regeneration blastema remain unclear. Here, I review the role of fibroblasts in salamander limb regeneration and how their activity compares with that of human fibroblasts. In addition, the question of whether salamander blastema tissue could induce regeneration and tumor regression in animals with a limited regeneration ability is discussed. A deeper understanding of these processes may lead to the development of novel regenerative and anticancer therapies.

Is a pacific coexistence between virus and host the unexploited path that may lead to an HIV functional cure?

The SupT1 cell line supports optimal HIV-1 replication, and prolonged in vitro replication in SupT1 cells renders the virus significantly less virulent. This raises the question of whether the infusion of SupT1 cells could be used as a cell-based therapy to induce a pacific coexistence between the HIV virus and its human host. In a recent study, I investigated this potential therapeutic strategy in vitro. The results suggested that this approach should be further explored in HIV-susceptible animal models. Such studies may lead to the development of a functional cure for HIV infection.

An initial in vitro investigation into the potential therapeutic use of SupT1 cells to prevent AIDS in HIV-seropositive individuals.

HIV infection usually leads to a progressive decline in number and functionality of CD4+ T lymphocytes, resulting in AIDS development. In this study, I investigated the strategy of using inoculated SupT1 cells to move infection from HIV-1 X4 strains toward the inoculated cells, which should theoretically prevent infection and depletion of normal CD4+ T cells, preventing the development of AIDS-related pathologies. Interestingly, the persistent in vitro replication in SupT1 cells renders the virus less cytopathic and more sensitive to antibody-mediated neutralization, suggesting that replication of the virus in the inoculated SupT1 cells may have a vaccination effect in the long run. In order to mimic the scenario of a therapy in which SupT1 cells are inoculated in an HIV-seropositive patient, I used infected SupT1/PBMC cocultures and a series of control experiments. Infections were done with equal amounts of the wild type HIV-1 LAI virus. The SupT1 CD4+CD8+ T cell population was distinguished from the PBMC CD4+CD8- T cell population by FACS analysis. The results of this study show that the virus-mediated killing of primary CD4+ T cells in the SupT1/PBMC cocultures was significantly delayed, suggesting that the preferential infection of SupT1 cells can induce the virus to spare primary CD4+ T cells from infection and depletion. The preferential infection of SupT1 cells can be explained by the higher viral tropism for the SupT1 cell line. In conclusion, this study demonstrates that it's possible in an in vitro system to use SupT1 cells to prevent HIV infection of primary CD4+ T cells, suggesting that further exploration of the SupT1 cell line as a cell-based therapy against HIV-1 may prove worthwhile.